


# THE ROLE OF CGRP IN MIGRAINE

Calli Leighann Cook, DNP, APRN, FNP-C


## Audience and Satisfaction



## BACKGROUND

Migraine is a considerable cause of morbidity and health care resource utilization worldwide. More than 1 billion people suffer from migraine, resulting in 45.1 million years of life lived with disability in 2016 and making migraine the leading cause of disability among people younger than 50 years. Despite the considerable disability and impairment associated with migraine, the disease continues to be underrecognized in clinical practice. While remaining undiagnosed is problematic for patients with treatable pain, an equally alarming issue is the high rate of misdiagnosis of migraine. Patients with migraine frequently receive misdiagnoses of chronic sinusitis, cervical pain, and even multiple sclerosis. This activity was designed to give learners the tools and perspective they need to make confident decisions to successfully treat patients with migraine and to overcome barriers that may impact patient outcomes.



## RESULTS



## Method


- Outcomes questions developed based on the learning objectives, with linkage to the needs assessment and content. Learners answered demographic, pre/post, evaluation and 60-day follow-up survey questions online
- Tests used to identify statistically significant differences pre to post:
  - Chi Square test for each of 10 multiple choice knowledge/case questions
  - Paired t test for % correct for each of 2 rating scale questions confidence questions
- $P \leq 0.05$  indicates a statistically significant difference
- Total records = 2241 (pre/post) and 2,172 (eval)
- Follow-up survey,  $n = 11$

## Confidence Level: Pre/Post



## Learning Objectives

- Describe the signs and symptoms of migraine as well as the diagnostic criteria for episodic and chronic migraine
- Explain the pathophysiology of migraine, including the pathogenic role of calcitonin gene-related peptide (CGRP)
- Explain how inhibition of CGRP can prevent and treat episodic and chronic migraine
- Assess the clinical efficacy and safety data surrounding new and emerging CGRP-targeted therapies



This activity was supported by an educational donation provided by Amgen